Beyond weight loss: How Semaglutide cuts heart risk faster than the scale moves
Doctors often prescribe semaglutide to help people manage type 2 diabetes or drop extra weight. Lately, though, its knack for shielding the heart has cardiologists buzzing. A deep dive into the SELECT trial reveals benefits that show up fast and stick around, even if the scale barely budges. This shift could change how we tackle heart risks in everyday patients.Digging into the select trial Researchers kicked off the SELECT trial back in 2018.It pulled in 17,604 adults from 41 countries, all carrying extra weight or obesity alongside proven cardiovascular disease, but no diabetes diagnosis. Ages ranged from 45 to 75,…